T-NeuroDx to Present Advances in Blood Test for Early Alzheimer's Detection at Major Conference
ALBUQUERQUE, NM, UNITED STATES, July 27, 2025 / EINPresswire.com / -- T-NeuroDx, a company pioneering new diagnostic tools that use abnormalities in the immune system to detect Alzheimer's Disease, will present its latest research at the 2025 Alzheimer's Association International Conference (AAIC) in Toronto, Canada, from July 27–31.
Dr. Christopher Wheeler, the company's Chief Science Officer, will share new findings about the company's promising blood test for Alzheimer's. The research focuses on identifying specific aged immune cells in the blood that act as an early warning sign, or 'biomarker,' for the disease.
A significant breakthrough in this new study is the enhancement of the test to be effective for all Alzheimer's patients, a critical step toward making this technology widely available. This builds upon Dr. Wheeler's initial discovery of the biomarker announced last year .
'We believe that studying the body's adaptive immune system will play a pivotal role in the early detection of Alzheimer's,' said Dr. Wheeler. 'Our results strengthen our case for a scalable, blood-based diagnostic that can move us closer to timely intervention and improved outcomes.'
T-NeuroDx's vision is to create simple, accessible blood tests that can help doctors diagnose Alzheimer's sooner, allowing for earlier treatment and better patient care.
Presentation Details:
• Poster Title: #107315 - Levels of age-related blood CD8 T cells binding a non-self peptide/HLA epitope track with Alzheimer's disease status in HLA-A2+ and HLA-A2- cohorts: a T cell biomarker assay applicable to all patients.
• Session: Biomarkers (non-neuroimaging) track.
• Event: Alzheimer's Association International Conference (AAIC) 2025
• Date: Monday, July 28, 2025
• Time: 7:30 AM – 4:15 PM EDT
• Location: Toronto, Canada
For more information about T-NeuroDx, please visit www.tneurodx.com
John Chavez
T-NeuroDx
+1 505-660-1046
[email protected]
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Tech Bytes: NASA launches solar-gazing spectrograph from White Sands
Jul. 27—A groundbreaking solar observation mission, launched from New Mexico, took less time than a typical lunch break this month. NASA on July 18 launched its Solar EruptioN Integral Field Spectrograph, or SNIFS, mission from White Sands Missile Range. The trip to observe the energy and dynamics of the chromosphere took less than 20 minutes, according to NASA. Scientists hope the mission answers questions about energy and mass flow in the chromosphere, high-frequency dynamics and the state of hydrogen's influence. Phil Chamberlin, principal investigator of the mission, told the Journal that NASA hasn't yet looked at the data, which will take a couple of weeks to obtain. The team will then spend months figuring out the images and analyzing the data, he said. "It is not a quick process," he added. ABQ's Sigma Science joining RSI EnTech Sigma Science Inc., an Albuquerque-based nuclear professional services agency founded in 1996, is joining Tennessee-based RSI EnTech. RSI serves clients in the environmental, nuclear, energy, construction and project delivery sectors, according to the company. RSI is a subsidiary of ASRC Industrial Services. The work aligns with that of Sigma Science, which has federal and commercial clients like the U.S. Department of Energy, National Nuclear Security Administration and U.S. Department of Defense. The acquisition will help RSI strengthen its capabilities and client base "to support national defense and energy initiatives across the nuclear industry," said RSI President Allison Getsi in a news release on July 18. "Today marks a fresh start as we unite with RSI and AIS," Sigma Science President Gil Torres said in a statement. "We remain dedicated to partnering with our clients and maintaining our reputation for exceptional performance as part of the RSI family." Raton fiber project breaks ground City and state leaders joined Resound Networks on Tuesday to break ground on a fiber project in Raton that will connect 1,370 homes, businesses, farms and public institutions like fire departments and libraries to high-speed internet. Resound Networks last year received $3.1 million from the state's Connect New Mexico Fund to lay out 30 miles of fiber in Colfax County, which includes Raton. "This project demonstrates how public-private partnerships can close the digital divide in rural New Mexico, bringing economic development and telehealth opportunities to Raton families," said Jeff Lopez, director of the state Office of Broadband Access and Expansion, in a statement. The internet service provider got nearly $20 million total through the program that's designed to build out internet infrastructure and expand broadband access in underserved or unserved communities in the state — of which there are many. The Governor's Office estimated in 2023 that nearly a quarter of New Mexican households don't have access to reliable, high-speed internet. Other grants awarded through the Connect New Mexico Fund will go toward work in more than a dozen rural counties and Pueblos. Space propulsion tech proves compatable Propel Space Inc., based out of Colorado, announced last week that its PM-5 gimbal technology works with space propulsion systems and will be available beginning in 2026 as part of Orbion Space Technology's thruster technologies package. New Mexico nonprofit NewSpace Nexus praised the work, as Propel Space is a participant in its incubator buildout program, NewSpace Ignitor. "Your journey since coming through the NewSpace Nexus Ignitor program has been truly remarkable," NewSpace Nexus posted on LinkedIn. "This collaboration, enabling enhanced maneuverability, reduced attitude determination and control system impacts and improved propellant efficiency for small spacecraft, is a testament to your innovation and dedication." Solve the daily Crossword
New York Times
9 hours ago
- New York Times
3 Out of 5 Liver Cancer Cases Are Preventable, Study Finds
Liver cancer kills more than 700,000 people a year. But three in five cases could be prevented, according to a comprehensive analysis published on Monday in the journal Lancet. The research found that prevention could be accomplished by addressing the disease's major causes: hepatitis B, hepatitis C, alcohol-associated liver disease and liver disease linked to metabolic risk factors like obesity. With nearly 900,000 new cases globally each year, liver cancer is the sixth most common cancer and the third leading cause of death from cancer. If cases continue to rise at the current rate, the number of new annual diagnoses will almost double, rising to 1.5 million globally in 2050, the study predicted. The researchers estimated that liver disease from alcohol use and metabolic dysfunction together would account for nearly one-third of new liver cancer cases by then. The findings align with what liver specialists have seen in their clinics for years. 'Liver cancer is common, it causes immense suffering and death, and the saddest part for me as a physician is that most of the cases are preventable,' said Dr. Brian P. Lee, an associate professor of medicine at the Keck School of Medicine at the University of Southern California, who was not involved in the study. Improved screening, vaccination and treatment in recent years have helped stem viral hepatitis, especially in the United States. But the threat of liver cancer from heavy alcohol use and metabolic dysfunction-associated steatotic liver disease, or MASLD, formerly known as nonalcoholic fatty liver disease, 'has been underrecognized and underestimated,' said Dr. Ahmed Kaseb, a professor of gastrointestinal medical oncology at the University of Texas MD Anderson Cancer Center, who was not associated with the study. A 'Highway' to Liver Cancer A vast majority of liver cancers arise in people with cirrhosis, said Dr. Hashem El-Serag, the chair of the department of medicine at Baylor College of Medicine in Texas and one of the authors of the new study. Cirrhosis, or advanced and largely irreversible scarring of the liver, damages healthy tissue and prevents the organ from working normally. Want all of The Times? Subscribe.
Indianapolis Star
9 hours ago
- Indianapolis Star
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases
Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is safe and well-tolerated in healthy elderly volunteers, showing a favourable pharmacokinetic profile and high brain penetration. These findings support the advancement of SUL-238 into further clinical development for Alzheimer's and other neurodegenerative diseases. ANKARA, TR / ACCESS Newswire / July 28, 2025 / GEN Pharmaceuticals ( Türkiye's leading specialty pharmaceutical company, announced positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class and novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. The findings were presented at the Alzheimer's Association International Conference 2025 (AAIC ®) in Toronto. This single oral ascending dose (SAD) Phase 1, first-in-human, randomized, double-blind, placebo-controlled study was conducted in three parts, involving a total of 53 healthy elderly adults. Part 1 included 6 cohorts (50, 100, 250, 500, 1000, and 2000 mg orally, n=23). In Part 2, the PK of a single 1000 mg oral dose was investigated in 10 healthy elderly adults. In Part 2B, the food effect was assessed using a randomized, single oral 2000 mg dose, two-treatment, two-period, crossover design (n=20). The trial results showed that single oral doses of 50-2000 mg of SUL-238 were safe and well-tolerated, while demonstrating a favourable PK profile and high cerebrospinal fluid (CSF) penetration. These findings make SUL-238 a promising candidate for further clinical development in neurodegenerative diseases, including Alzheimer's disease. No adverse effects (AEs) limited dose escalation, AE rates were comparable between SUL-238 and placebo, and all AEs were mild or moderate. The mean terminal elimination half-life was 0.86-3.80 hours, and the time to maximum plasma concentration was 0.50-1.39 hours. Under fed conditions, maximum plasma concentration (C max) and area under the plasma concentration-time curve (AUC 0-∞) decreased by 50% and 60%, respectively. CSF-to-plasma percentages at 2 and 8 hours post-dose were 21.1% (±6.6%) and 74.2% (±46.0%). Abidin Gülmüş, Chairman of GEN, stated: 'We are very encouraged by these promising first-in-human results, marking an important step forward in our mission to address the underlying biology of Alzheimer's disease.' Nadir Ulu, MD, PhD, Vice President of R&D at GEN, added: 'With its excellent safety and PK profile in this Phase 1 trial, combined with robust preclinical data, SUL-238 represents a strong candidate for further clinical development to meet the critical unmet needs in neurodegenerative diseases, including Alzheimer's disease.' About SUL-238 SUL-238 is a novel, first-in-class, hibernation-derived small molecule that targets mitochondria, the cell's 'powerhouse.' It supports mitochondrial bioenergetics via complex I/IV activation and has improved mitochondrial function in rodent models of neurodegenerative, cardiovascular, and renal diseases, as well as aging. SUL-238 crosses the blood-brain barrier and has undergone extensive safety evaluation in preclinical and Phase 1 studies. GEN licenses SUL-238 from Sulfateq BV for neurodegenerative disease applications. About GEN: Founded in 1998, GEN is Türkiye's leading specialty pharmaceutical company, focused on developing innovative therapies across multiple therapeutic areas. GEN manufactures high-quality, competitive products at its GMP-certified facility and pursues original drug development through two dedicated R&D centers and investments. About Sulfateq: Sulfateq B.V. is an early-stage Dutch biotech company that fosters strategic collaborations with academic and industrial research centers to accelerate the development of innovative new medicines. It has developed a novel class of small molecules, the SUL-compounds, that maintain mitochondrial health. Contact Information Bulutay Güneş Sr. Head of Corporate Brand Ali Ketencioğlu Investor Relations Manager Kees van der Graaf Sulfateq CEO View the original press release on ACCESS Newswire The post GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases appeared first on DA80 Hub.
